Bone Marrow Transplantation最新文献

Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. 贝卢莫司地联合疗法在实际临床实践中治疗慢性移植物抗宿主病。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-18 DOI: 10.1038/s41409-024-02476-z

Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer, Lori Muffly, Parveen Shiraz, Matthew J Frank, Andrew R Rezvani, Sushma Bharadwaj, Wen-Kai Weng, Judith A Shizuru, Sally Arai

引用次数: 0

Successful allogeneic CD34⁺ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). B细胞急性淋巴细胞白血病患者接受CAR T细胞疗法后，成功通过异体CD34+造血干细胞增殖治疗缓解长期细胞减少症。代表西班牙造血移植和细胞疗法小组（GETH-TC）。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-17 DOI: 10.1038/s41409-024-02473-2

Águeda Molinos-Quintana, Nuria Martínez-Cibrian, Anna Alonso-Saladrigues, Víctor Galán-Gómez, Rebeca Bailén, Susana Buendía-López, Carolina Fuentes-Socorro, Mi Kwon, Marta González-Vincent, Concepción Pérez de Soto, Berta González-Martínez, Susana Rives, José María Pérez-Hurtado, Valentín Ortiz-Maldonado, José Antonio Pérez-Simón

引用次数: 0

Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study. 急性髓细胞性白血病患者异基因干细胞移植后MRD阳性的移植前风险因素：一项前瞻性研究。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-16 DOI: 10.1038/s41409-024-02466-1

Si-Qi Li, Chun-Zi Yu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, Xiao-Jun Huang, Ying-Jun Chang

{"title":"Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.","authors":"Si-Qi Li, Chun-Zi Yu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Yu-Qian Sun, Chen-Hua Yan, Meng Lv, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, Xiao-Jun Huang, Ying-Jun Chang","doi":"10.1038/s41409-024-02466-1","DOIUrl":"https://doi.org/10.1038/s41409-024-02466-1","url":null,"abstract":"We aimed to prospectively explore the risk factors for measurable residual disease (MRD) positivity after allogeneic stem cell transplantation (allo-SCT) in AML patients (n = 478). The cumulative incidences (CIs) of post-SCT MRD positivity at 100 days, 360 days and 3 years were 4.6%, 12.1% and 18.3%, respectively. Positive pre-SCT MRD and pre-SCT active disease were risk factors for post-SCT MRD positivity at both 360 days and 3 years (P < 0.001). European LeukemiaNet (ELN) 2017 risk stratification was a risk factor for positive post-SCT MRD at 360 days (P = 0.044). A scoring system for predicting post-SCT MRD positivity at 360 days was established by using pre-SCT MRD, pre-SCT active disease and ELN 2017 risk stratification. The CI of positive post-SCT MRD at 3 years was 13.2%, 23.7%, and 43.9% for patients with scores of 0, 1, and 2, respectively (P < 0.001). Multivariate analysis demonstrated that the scoring system was associated with a higher CI of post-SCT MRD positivity, leukemia relapse and inferior survival. Our data indicate that positive pre-SCT MRD status, pre-SCT active disease, and ELN 2017 risk stratification are risk factors for positive post-SCT MRD status in AML patients.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma. 用移植后环磷酰胺加依维莫司预防难治性T细胞和B细胞淋巴瘤的GvHD。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-15 DOI: 10.1038/s41409-024-02472-3

Tim Richardson, Hishan Tharmaseelan, Lukas Frenzel, Philipp Gödel, Moritz Fürstenau, Pascal Nieper, Till Braun, Daniel Schütte, Michael Hallek, Christof Scheid, Udo Holtick

引用次数: 0

Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. EBMT 细胞治疗和免疫生物学工作组就异体造血干细胞移植后使用供体淋巴细胞输注提出的 2024 年最佳实践建议的实用性。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-15 DOI: 10.1038/s41409-024-02458-1

Anne-Claire Mamez, Amandine Pradier, Sarah Morin, Federica Giannotti, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Federico Simonetta

引用次数: 0

Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial. 骨髓瘤患者干细胞动员与化疗和细胞因子（G-CSF）与单纯细胞因子的比较（MOCCCA）：随机II期、开放标签、非劣效试验。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-15 DOI: 10.1038/s41409-024-02468-z

Barbara Jeker, Laura Thalmann, Ulrike Bacher, Henning Nilius, Gaëlle Rhyner, Martin Sökler, Susanne Soltermann, Annette Winkler, Corinne Vorburger, Michael Daskalakis, Michèle Hoffmann, Thomas Pabst

{"title":"Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.","authors":"Barbara Jeker, Laura Thalmann, Ulrike Bacher, Henning Nilius, Gaëlle Rhyner, Martin Sökler, Susanne Soltermann, Annette Winkler, Corinne Vorburger, Michael Daskalakis, Michèle Hoffmann, Thomas Pabst","doi":"10.1038/s41409-024-02468-z","DOIUrl":"https://doi.org/10.1038/s41409-024-02468-z","url":null,"abstract":"In fit patients with newly diagnosed myeloma, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is considered standard of care. For mobilization of CD34+ cells for ASCT, combined cytotoxic chemotherapy and G-CSF is commonly used. However, the importance of cytostatic chemotherapy for reliable mobilization remains unclear. This prospective randomized phase II non-inferiority trial compared G-GSF only (G) compared to standard chemotherapy/G-CSF (CG) for CD34+ mobilization. The primary endpoint was a less than 15% difference in successful stem cell collection ( ≥ 5.0 × 106 CD34+ cells/kg b.w. in a single day collection procedure without additional stimulation with plerixafor) with the G regimen. 136 patients were 1:1 randomized. With an 18% difference in favor of the CG therapy, the non-inferiority margin was not maintained (95% CI 1%, 34%, p = 0.04). The median total CD34+ yield was 9.99 × 106/kg b.w. in CG patients and 7.42 × 106/kg b.w. in patients with G-CSF alone (p < 0.001). Ultimately, 130 (96%) patients proceeded to HDCT with ASCT. There were no differences in adverse events, hematologic engraftment, quality of life, or pain perception between the groups. Our data indicate that G-CSF only is inferior to chemotherapy with G-CSF for peripheral CD34+ stem cell mobilization. Trial registration SNCTP #: SNCTP000002952; Trials.gov #: NCT03442673.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group. 更正：2022-2023年中国造血干细胞移植活动。干细胞来源中外周血的比例持续增长：中国造血干细胞移植登记组的报告。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-15 DOI: 10.1038/s41409-024-02438-5

Lan-Ping Xu, Pei-Hua Lu, De-Pei Wu, He Huang, Er-Lie Jiang, Dai-Hong Liu, Wei-Jie Cao, Xi Zhang, Yue-Wen Fu, Nai-Nong Li, Xin-Chuan Chen, Xiao-Yu Zhu, Qi-Fa Liu, Ling-Hui Xia, Yi-Cheng Zhang, Ya-Jing Xu, Fu-Chun Li, Jiong Hu, Si-Xi Liu, Rong-Rong Liu, Xiao-Di Ma, Xiao-Wen Tang, Yi Luo, Xiao-Hui Zhang, Xiao-Jun Huang

引用次数: 0

Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation. 评估接受造血细胞移植的婴幼儿的氟达拉滨标准剂量和相应暴露量。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-13 DOI: 10.1038/s41409-024-02467-0

Julia Möhlmann, Lisanne van der Ploeg, Jurgen Langenhorst, Tim Bognàr, Kim van der Elst, Marc Bierings, Alwin Huitema, Aurelia de Vries Schultink, Caroline Lindemans

引用次数: 0

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. NPM1 突变急性髓性白血病的分子可测量残留疾病监测和移植适应症。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-13 DOI: 10.1038/s41409-024-02465-2

Mary R Christopher, Mariam T Nawas, John L Reagan

{"title":"Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.","authors":"Mary R Christopher, Mariam T Nawas, John L Reagan","doi":"10.1038/s41409-024-02465-2","DOIUrl":"https://doi.org/10.1038/s41409-024-02465-2","url":null,"abstract":"NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or intermediate-risk according to the European Leukemia Net stratification. Some patients, however, either have a poor response to initial intensive chemotherapy or ultimately relapse. NPM1 mutations are common, generally stable at early relapse and AML specific, features which make them ideal targets for measurable residual disease (MRD) monitoring. MRD monitoring via molecular analysis during the course of treatment can inform the role of allogeneic stem cell transplantation (HCT) in first remission in patients with NPM1 mutated AML with high-risk co-occurring mutations, particularly FLT3-ITD, and in favorable risk patients who do not achieve defined molecular milestones. In this review, we evaluate the prognostic role of MRD monitoring in NPM1 mutated AML and its use as a predictive biomarker to refine risk stratification and inform decision making regarding treatment. We explore the impact of pre-HCT MRD positivity on post-HCT outcomes in this AML subset, and how HCT-related factors such as conditioning intensity may influence this risk.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142614619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma. 非霍奇金淋巴瘤 CAR-T 细胞疗法失败后的应对策略。

IF 4.5 2区医学

Bone Marrow Transplantation Pub Date : 2024-11-12 DOI: 10.1038/s41409-024-02463-4

Xiaotian Zhang, Kailin Xu, Robert Peter Gale, Bin Pan

引用次数: 0